X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Packaging & Logistic

Vetter looks ahead to further expansions to meet supply chain demand

Content Team by Content Team
20th October 2023
in Packaging & Logistic, Press Statements
Full service: the expertise and efficiency of a one-stop shop

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), announces additional investments as part of its long-term dedication to customer partnerships. Vetter’s extensive 40+ years of experience in aseptic filling and packaging shows a consistent desire for sustainable growth and corporate development. The pharmaceutical service provider plans with future-driven considerations to meet its long-lead goals for continued expansion and customer satisfaction.

Vetter is investing 230 million euros in its new production building, which is currently under construction at the global corporate headquarters site in Ravensburg, Germany. The company recently reached a significant milestone in the construction process, as the shell of the building is now complete, following the start of construction in November 2021. The building is 122m long, 44m wide and 32m tall and will feature several new commercial filling lines to effectively increase aseptic manufacturing capacity for its global customer base. Vetter plans to install the first cleanrooms by the end of 2024.

According to Vetter Managing Director Thomas Otto, “Our new production building signifies our ongoing dedication to support the needs of our customers concerning their complex injectable drug products with regards to packaging systems, specific process requirements and batch sizes. This is just one of several investments we are currently undertaking to manage our sustainable growth.”

Further investments include the increase of lab space for analytical services, the expansion of filling capacity through new commercial production lines at other sites in the EU, the expansion in cool storage and warehousing, as well as a new technical equipment warehouse. Added to this are the optimization of infrastructure at all global sites to further develop processes, the development of new compounding and preparation rooms, and as a result, the optimization of the handling incoming and outgoing products.

“In our industry, the needs of our customers and the patients they serve continue to evolve,” emphasizes Vetter Managing Director Peter Soelkner. “Our job as a leading CDMO is to act as a strong partner, take the proactive steps necessary to identify relevant industry trends, and thus, to meet the evolving demands of the market through offering adequate resources. Over the coming years, we will continue to make further investments to stay on track with this commitment that we have made as a service provider, from the early development phase to aseptic fill and finish through assembly and packaging services.”

Previous Post

Veramed expands its global footprint by acquiring Clinical Trial Data Services

Next Post

CDMO-Biotech Ties Help Cut Business Risk In Drug Development

Related Posts

Pharma Advancement Banner
Press Statements

Welcome to the Inaugural Operationalize: Expanded Access Programs Summit West

27th June 2025
Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
ACHEMA
Middle East and South Asia

ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show

9th May 2025
Press Statements

APM Steam Highlights Comprehensive HVAC Insulation Services for Biopharmaceutical and Pharmaceutical Facilities

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Americas

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

4th March 2025
Next Post
Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

CDMO-Biotech Ties Help Cut Business Risk In Drug Development

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In